Different strategies to overcome multidrug resistance in cancer

Biotechnology Advances

Volumn 31, Issue 8, 2013, Pages 1397-1407

  Saraswathy, Manju ^a   Gong, Shaoqin ^a  

^a University of Wisconsin Madison   (United States)

Author keywords

Anticancer agents; Cancer; Chemosensitizers; Multidrug resistance; Nanocarriers; RNAi therapy

Indexed keywords

ANTI-CANCER AGENTS; CANCER; CHEMOSENSITIZERS; MULTIDRUG RESISTANCE; NANO-CARRIERS; RNAI THERAPY;

CELLS; CHEMOTHERAPY;

DISEASES;

CANCER; CHEMOTHERAPY; DRUG RESISTANCE; HEALTH RISK; RNA;

ANTINEOPLASTIC AGENT; DRUG CARRIER; NANOPARTICLE;

ANIMAL; ANTICANCER AGENTS; CHEMOSENSITIZERS; DRUG RESISTANCE; HUMAN; MOUSE; MULTIDRUG RESISTANCE; NANOCARRIERS; NEOPLASM; RAT; REVIEW; RNA INTERFERENCE; RNAI THERAPY;

ANTICANCER AGENTS; CANCER; CHEMOSENSITIZERS; MULTIDRUG RESISTANCE; NANOCARRIERS; RNAI THERAPY;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG CARRIERS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HUMANS; MICE; NANOPARTICLES; NEOPLASMS; RATS; RNA INTERFERENCE;

EID: 84887992978     PISSN: 07349750     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biotechadv.2013.06.004     Document Type: Review

References (153)

1. Aagaard L., Rossi J.J. RNAi therapeutics: principles, prospects and challenges. Adv Drug Deliv Rev 2007, 59:75-86.
2. Adams M.L., Lavasanifar A., Kwon G.S. Amphiphilic block copolymers for drug delivery. J Pharm Sci 2003, 92:1343-1355.
3. Aggarwal B.B., Shishodia S. Molecular targets of dietary agents for prevention and therapy of cancer. Biochem Pharmacol 2006, 71:1397-1421.
4. Aggarwal B.B., Kumar A., Bharti A.C. Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res 2003, 23:363-398.
5. Aggarwal B.B., Bhardwaj A., Aggarwal R.S., Seeram N.P., Shishodia S., Takada Y. Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies. Anticancer Res 2004, 24:2783-2840.
6. Alexis F., Pridgen E., Molnar L.K., Farokhzad O.C. Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharmaceutics 2008, 5:505-515.
7. Allavena P., Signorelli M., Chieppa M., Erba E., Bianchi G., Marchesi F., et al. Anti-inflammatory properties of the novel antitumor agent yondelis (trabectedin): inhibition of macrophage differentiation and cytokine production. Cancer Res 2005, 65:2964-2971.
8. Alvarez-Lorenzo C., Sosnik A., Concheiro A. PEO-PPO block copolymers for passive micellar targeting and overcoming multidrug resistance in cancer therapy. Curr Drug Targets 2011, 12:1112-1130.
9. Amarzguioui M., Rossi J.J., Kim D. Approaches for chemically synthesized siRNA and vector-mediated RNAi. FEBS Lett 2005, 579:5974-5981.
10. Anuchapreeda S., Leechanachai P., Smith M.M., Ambudkar S.V., Limtrakul P.N. Modulation of P-glycoprotein expression and function by curcumin in multidrug-resistant human KB cells. Biochem Pharmacol 2002, 64:573-582.
11. Baghel S.S., Shrivastava N., Baghel R.S., Agrawal P., Rajput S. A review of quercetin: antioxidant and anticancer properties. World J Pharm Pharm Sci 2012, 1:146-160.
12. Baguley B.C. Multidrug resistance in cancer. Methods Mol Biol 2010, 596:1-14.
13. Bentires-Alj M., Barbu V., Fillet M., Chariot A., Relic B., Jacobs N., et al. NF-kappaβ transcription factor induces drug resistance through MDR1 expression in cancer cells. Oncogene 2003, 22:90-97.
14. Bilan W., Maling G., Xiuling Z., Xiawei W., Changyang G., Xiuhong W., et al. Co-delivery honokiol and doxorubicin in MPEG-PLA nanoparticles. J Nanosci Nanotechnol 2010, 10:4166-4172.
15. Binkhathlan Z., Shayeganpour A., Brocks D.R., Lavasanifar A. Encapsulation of P-glycoprotein inhibitors by polymeric micelles can reduce their pharmacokinetic interactions with doxorubicin. Eur J Pharm Biopharm 2012, 81:142-148.
16. Bogush T., Robert J. Multidrug resistance reversal in solid tumors. ABC Transporters and Multidrug Resistance 2009, 349-357. John Wiley & Sons, Inc, New Jersey. A. Boumendjel, J. Boutonnat, J. Robert (Eds.).
17. Booser D.J., Hortobagyi G.N. Anthracycline antibiotics in cancer therapy: focus on drug resistance. Drugs 1994, 47:223-258.
18. Borska S., Chmielewska M., Wysocka T., Drag-Zalesinska M., Zabel M., Dziegiel P. In vitro effect of quercetin on human gastric carcinoma: targeting cancer cells death and MDR. Food Chem Toxicol 2012, 50:3375-3383.
19. Byrne J.D., Betancourt T., Brannon-Peppas L. Active targeting schemes for nanoparticle systems in cancer therapeutics. Adv Drug Deliv Rev 2008, 60:1615-1626.
20. Carmeliet P., Jain R.K. Angiogenesis in cancer and other diseases. Nature 2000, 407:249-257.
21. Chang I.Y., Kim M.H., Kim H.B., Lee Y.D., Kim S.H., Kim H.Y., et al. Small interfering RNA-induced suppression of ERCC1 enhances sensitivity of human cancer cells to cisplatin. Biochem Biophys Res Commun 2005, 327:225-233.
22. Chaturvedi K., Ganguly K., Kulkarni A.R., Kulkarni V.H., Nadagouda M.N., Rudzinski W.E., et al. Cyclodextrin-based siRNA delivery nanocarriers: a state-of-the-art review. Expert Opin Drug Deliv 2011, 8:1455-1468.
23. Chen A.M., Zhang M., Wei D., Stueber D., Taratula O., Minko T., et al. Co-delivery of doxorubicin and Bcl-2 siRNA by mesoporous silica nanoparticles enhances the efficacy of chemotherapy in multidrug-resistant cancer cells. Small 2009, 5:2673-2677.
24. Cheng A.L., Hsu C.H., Lin J.K., Hsu M.M., Ho Y.F., Shen T.S. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res 2001, 21:2895-2900.
25. Choi J.S., Piao Y.J., Kang K.W. Effects of quercetin on the bioavailability of doxorubicin in rats: role of CYP3A4 and P-gp inhibition by quercetin. Arch Pharm Res 2011, 34:607-613.
26. Chow T.Y.-K., Alaoui-Jamali M.A., Yeh C., Yuen L., Griller D. The DNA double-stranded break repair protein endo-exonuclease as a therapeutic target for cancer. Mol Cancer Ther 2004, 3:911-919.
27. Coley H.M. Mechanisms and strategies to overcome chemotherapy resistance in metastatic breast cancer. Cancer Treat Rev 2008, 34:378-390.
28. Cortes J., Baselga J. Targeting the microtubules in breast cancer beyond taxanes: the epothilones. Oncologist 2007, 12:271-280.
29. Creixell M., Peppas N.A. Co-delivery of siRNA and therapeutic agents using nanocarriers to overcome cancer resistance. Nano Today 2012, 7:367-379.
30. Dalton W.S., Scheper R.J. Lung resistance-related protein: determining its role in multidrug resistance. J Natl Cancer Inst 1999, 91:1604-1605.
31. Davis M.E., Chen Z.G., Shin D.M. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov 2008, 7:771-782.
32. de Fougerolles A.R. Delivery vehicles for small interfering RNA in vivo. Hum Gene Ther 2008, 19:125-132.
33. Dempsey C.E., Roberts D.L., Dive C. Bax, Bak and Bid: key mediators of apoptosis. Apoptosis and Cancer Therapy: From Cutting-edge Science to Novel Therapeutic Concepts 2008, 346-378. Wiley-VCH Verlag GmbH, Germany. K.M. Debatin, S. Fulda (Eds.).
34. Dhule S.S., Penfornis P., Frazier T., Walker R., Feldman J., Tan G., et al. Curcumin-loaded γ-cyclodextrin liposomal nanoparticles as delivery vehicles for osteosarcoma. Nanomed Nanotechnol 2012, 8:440-451.
35. Dole D., Nuñez G., Merchant A.K., Maybaum J., Rode C.K., Bloch C.A., et al. Bcl-2 inhibits chemotherapy-induced apoptosis in neuroblastoma. Cancer Res 1994, 54:3253-3259.
36. Duan Z., Brakora K.A., Seiden M.V. Inhibition of ABCB1 (MDR1) and ABCB4 (MDR3) expression by small interfering RNA and reversal of paclitaxel resistance in human ovarian cancer cells. Mol Cancer Ther 2004, 3:833-838.
37. Duan J., Mansour H.M., Zhang Y., Deng X., Chen Y., Wang J., et al. Reversion of multidrug resistance by co-encapsulation of doxorubicin and curcumin in chitosan/poly(butyl cyanoacrylate) Nanoparticles. Int J Pharm 2012, 426:193-201.
38. Endoh T., Ohtsuki T. Cellular siRNA delivery using cell-penetrating peptides modified for endosomal escape. Adv Drug Deliv Rev 2009, 61:704-709.
39. Engi H., Vasas A., Rédei D., Molnár J., Hohmann J. New MDR modulators and apoptosis inducers from Eiphorbia species. Anticancer Res 2007, 27:3451-3458.
40. Ferry D.R., Traunecker H., Ker D.J. Clinical trials of P-glycoprotein reversal in solid tumors. Eur J Cancer A 1996, 32:1070-1081.
41. Filipits M. Mechanisms of cancer: multidrug resistance. Drug Discov TodayDis Mech 2004, 1:229-234.
42. Flörsheimer A., Altmann K.H. Epothilones and their analogues: a new class of promising microtubule inhibitors. Expert Opin Ther Pat 2001, 11:951-968.
43. Ganta S., Amiji M. Co-administration of paclitaxel and curcumin in nanoemulsion formulations to overcome multidrug resistance in tumor cells. Mol Pharmaceutics 2009, 6:928-939.
44. Garraway L.A., Janne P.A. Circumventing cancer drug resistance in the era of personalized medicine. Cancer Discov 2012, 2:214-226.
45. Gartel A.L., Kandel E.S. RNA interference in cancer. Biomol Eng 2006, 23:17-34.
46. Gary J.D., Puri N., Won Y.Y. Polymer-based siRNA delivery: perspectives on the fundamental and phenomenological distinctions from polymer-based DNA delivery. J Control Release 2007, 12:64-73.
47. Giacomini K.M., Huang S.M., Tweedie D.J., Benet L.Z., Brouwer K.L., Chu X., et al. Membrane transporters in drug development. Nat Rev Drug Discov 2010, 9:215-236.
48. Gillet J.P., Efferth T., Remacle J. Chemotherapy-induced resistance by ATP-binding cassette transporter genes. Biochim Biophys Acta 2007, 1775:237-262.
49. Glienke W., Maute L., Wicht J., Bergmann L. Wilms' tumor gene 1 (WT1) as a target in curcumin treatment of pancreatic cancer cells. Eur J Cancer 2009, 45:874-880.
50. Gottesman M.M., Fojo T., Bates S.E. Multidrug resistance in cancer: role of ATP dependent transporters. Nat Rev Cancer 2002, 2:48-58.
51. Hao Y.X., He Z.W., Zhu J.H., Shen Q., Sun J.Z., Du N., et al. Reversal of multidrug resistance in renal cell carcinoma by short hairpin RNA targeting MDR1 gene. Chin Med J 2012, 125:2741-2745.
52. Hilary T., Coley H.M. Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting P-glycoprotein. Cancer Control 2003, 10:159-165.
53. Hillaireau H., Couvreur P. Nanocarriers' entry into the cell: relevance to drug delivery. Cell Mol Life Sci 2009, 66:2873-2896.
54. Hodgkinson V.C., Eagle G.L., Drew P.J., Lind M.J., Cawkwell L. Biomarkers of chemotherapy resistance in breast cancer identified by proteomics: current status. Cancer Lett 2010, 294:13-24.
55. FDA Approval for Ixabepilone [Accessed May 28, 2013]. http://www.cancer.gov/cancertopics/druginfo/fda-ixabepilone.
56. Cancer Facts & Figures Available at, (Accessed January 15, 2012). http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-031941.pdf.
57. Huang W.C., Hung M.C. Induction of Akt activity by chemotherapy confers acquired resistance. J Formos Med Assoc 2009, 108:180-194.
58. Huang C., Xu D., Xia Q., Wang P., Rong C., Su Y. Reversal of P-glycoprotein-mediated multidrug resistance of human hepatic cancer cells by Astragaloside II. J Pharm Pharmacol 2012, 64:1741-1750.
59. Iversen T.G., Skotland T., Sandvig K. Endocytosis and intracellular transport of nanoparticles: present knowledge and need for future studies. Nano Today 2011, 6:176-185.
60. Jäger A.C., Rasmussen M., Bisgaard H.C., Singh K.K., Nielsen F.C., Rasmussen L.J. HNPCC mutations in the human DNA mismatch repair gene hMLH1 influence assembly of hMutLα and hMLH1-hEXO1 complexes. Oncogene 2001, 20:3590-3595.
61. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J Clin 2011, 61:69-90.
62. Joe B., Lokesh B.R. Role of capsaicin, curcumin and dietary n-3 fatty acids in lowering the generation of reactive oxygen species in rat peritoneal macrophages. Biochim Biophys Acta 1994, 1224:255-263.
63. Johnson W.W. P-glycoprotein-mediated efflux as a major factor in the variance of absorption and distribution of drugs: modulation of chemotherapy resistance. Methods Find Exp Clin Pharmacol 2002, 24:501-514.
64. Ke W., You P., Wang J., Wang R., Guo C., Zhou L., et al. MCF-7/ADR cells (re-designated NCI/ADR-RES) are not derived from MCF-7 breast cancer cells: a loss for breast cancer multidrug-resistant research. Med Oncol 2011, 28:135-141.
65. Kim D.H., Rossi J.J. Strategies for silencing human disease using RNA interference. Nat Rev Genet 2007, 8:173-184.
66. Kim J.H., Gupta S.C., Park B., Yadav V.R., Aggarwal B.B. Turmeric (Curcuma longa) inhibits inflammatory nuclear factor (NF)-κB and NF-κB-regulated gene products and induces death receptors leading to suppressed proliferation, induced chemosensitization, and suppressed osteoclastogenesis. Mol Nutr Food Res 2012, 56:454-465.
67. Kittima K., Chiablaem K., Wacharasindhu S., Lirdprapamongkol K., Svasti J., Vchirawongkwin V., et al. Paclitaxel delivery using carrier made from curcumin derivative: synergism between carrier and the loaded drug for effective cancer treatment. J Pharm Sci 2012, 101:3779-3786.
68. Kivisto K.T., Kroemer H.K., Eichelbaum M. The role of human cytochrome P450 enzymes in the metabolism of anticancer agents: implications for drug interactions. Br J Clin Pharmacol 1995, 14:523-530.
69. Klibanov A.L., Maruyama K., Torchilin V.P., Huang L. Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes. FEBS Lett 1990, 268:235-237.
70. Kruczynski A., Poli M., Dossi R., Chazottes E., Berrichon G., Ricome C., et al. Anti-angiogenic, vascular-disrupting and anti-metastatic activities of vinflunine, the latest vinca alkaloid in clinical development. Eur J Cancer 2006, 42:2821-2832.
71. Lage H. An overview of cancer multidrug resistance: a still unsolved problem. Cell Mol Life Sci 2008, 65:3145-3167.
72. Lage H. Proteomics approaches for investigation of therapy resistance in cancer. Proteomics Clin Appl 2009, 3:883-911.
73. Lee C.H. Reversing agents for ATP-binding cassette (ABC) transporters: application in modulating multidrug resistance (MDR). Curr Med Chem Anti Cancer Agents 2004, 4:43-52.
74. Lee J.J., Swain S.M. Development of novel chemotherapeutic agents to evade the mechanisms of multidrug resistance (MDR). Semin Oncol 2005, 32:S22-S26.
75. Li Y.T., Chua M.J., Kunnath A.P., Chowdhury E.H. Reversing multidrug resistance in breast cancer cells by silencing ABC transporter genes with nanoparticle-facilitated delivery of target siRNAs. Int J Nanomedicine 2012, 7:2473-2481.
76. Limtrakul P., Siwanon S., Yodkeeree S., Duangrat C. Effect of Stemona curtisii root extract on P-glycoprotein and MRP-1 function in multidrug-resistant cancer cell. Phytomedicine 2007, 14:381-389.
77. Lin J.N., Lin V.C.H., Rau K.M., Shieh P.C., Kuo D.H., Shieh J.C., et al. Resveratrol modulates tumor cell proliferation and protein translation via SIRT1-dependent AMPK activation. J Agric Food Chem 2010, 58:1584-1592.
78. Liscovitch M., Lavie Y. Cancer multidrug resistance: a review of recent drug discovery research. I Drugs 2002, 5:349-355.
79. Liscovitch M., Ravid D. A Case study of mis identification of cancer cell lines: MCF-7/AdrR cell (re-designated as NCI/ADR-RES) are derived from OVCAR-8 human ovarian carcinoma cells. Cancer Lett 2007, 245:350-352.
80. Lu J.J., Cai Y.J., Ding J. The short-time treatment with curcumin sufficiently decreases cell viability, induces apoptosis and copper enhances these effects in multidrug-resistant K562/A02 cells. Mol Cell Biochem 2012, 360:253-260.
81. Maeda H. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv Enzyme Regul 2001, 41:189-207.
82. Maeda H., Wu J., Sawa T., Matsumura Y., Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 2000, 65:271-284.
83. Metzger-Filho O., Moulin C., de Azambuja E., Ahmad A. Larotaxel: broadening the road with new taxanes. Expert Opin Investig 2009, 18:1183-1189.
84. Misra R., Sahoo S.K. Coformulation of doxorubicin and curcumin in poly (D, L-lactide-co-glycolide) nanoparticles suppresses the development of multidrug resistance in K562 cells. Mol Pharmaceutics 2011, 8:852-866.
85. Muñoz-Martínez F., Lu P., Cortés-Selva F., Pérez-Victoria J.M., Jiménez I.A., Ravelo A.G., et al. Celastraceae sesquiterpenes as a new class of modulators that bind specifically to human P-glycoprotein and reverse cellular multidrug resistance. Cancer Res 2004, 64:7130-7138.
86. Navarro G., Sawant R.R., Biswas S., Essex S., de Ilarduya C.T., Torchilin V.P. P-glycoprotein silencing with siRNA delivered by DOPE-modified PEI overcomes doxorubicin resistance in breast cancer cells. Nanomedicine 2012, 7:65-78.
87. Nessa M.U., Beale P., Chan C., Yu J.Q., Huq F. Combinations of resveratrol, cisplatin and oxaliplatin applied to human ovarian cancer cells. Anticancer Res 2012, 32:53-59.
88. Newman M.J., Rodarte J.C., Benbatoul K.D., Romano S.J., Zhang C., Krane S., et al. Discovery and characterization of OC144-093, a novel inhibitor of P-glycoprotein mediated multidrug resistance. Cancer Res 2000, 60:2964-2972.
89. Nieth C., Priebsch A., Stege A., Lage H. Modulation of the classical multidrug resistance (MDR) phenotype by RNA interference (RNAi). FEBS Lett 2003, 545:144-150.
90. Nitiss J.L. Targeting DNA, topoisomerase II in cancer chemotherapy. Nat Rev Cancer 2009, 9:338-350.
91. Oshika Y., Nakamura M., Tokunaga T., Fukushima Y., Abe Y., Ozeki Y., et al. Multidrug resistance-associated protein and mutant p53 protein expression in nonsmall cell lung-cancer. Mod Pathol 1998, 11:1059-1063.
92. Otsuka H., Nagasaki Y., Kataoka K. PEGylated nanoparticles for biological and pharmaceutical applications. Adv Drug Deliv Rev 2012, 16:246-255.
93. Ozben T. Mechanisms and strategies to overcome multiple drug resistance in cancer. FEBS Lett 2006, 580:2903-2909.
94. Pai S.I., Lin Y.Y., Macaes B., Meneshian A., Hung C.F., Wu T.C. Prospects of RNA interference therapy for cancer. Gene Ther 2006, 13:464-477.
95. Palakurthi S., Yellepeddi V.K., Vangara K.K. Recent trends in cancer drug resistance reversal strategies using nanoparticles. Expert Opin Drug Deliv 2012, 9:287-301.
96. Patel N.R., Rathi A., Mongayt D., Torchilin V.P. Reversal of multidrug resistance by co-delivery of tariquidar (XR9576) and paclitaxel using long-circulating liposomes. Int J Pharm 2011, 416:296-299.
97. Pichler A., Zelcer N., Prior J.L., Annemieke K.J., Piwnica-Worms D. In vivo RNA interference-mediated ablation of MDR1 P-glycoprotein. Clin Cancer Res 2005, 11:4487-4494.
98. Pichu S., Krishnamoorthy S., Shishkov A., Zhang B., McCue P., Ponnappa B.C. Knockdown of Ki-67 by dicer-substrate small interfering RNA sensitizes bladder cancer cells to curcumin-induced tumor inhibition. PLoS One 2012, 7:e48567.
99. Prabaharan M., Grailer J.J., Steeber D.A., Gong S. Thermo-sensitive micelles based on folate-conjugated poly(N-vinylcaprolactam)-block-poly(ethylene glycol) copolymers for tumor-targeted drug delivery. Macromol Biosci 2009, 9:744-753.
100. Pramanik D., Nathaniel C.R., Das S., Gupta S., Chenna V., Bisht S., et al. A composite polymer nanoparticle overcomes multidrug resistance and ameliorates doxorubicin-associated cardiomyopathy. Oncotarget 2012, 3:640-650.
101. Prasad P., Ping P., Shuhendler A., Rauth A.M., Wu X.Y. Doxorubicin and mitomycin C co-loaded polymer-lipid hybrid nanoparticles inhibit growth of sensitive and multidrug resistant human mammary tumor xenografts. Cancer Lett 2012, 12:S0304-S3835.
102. Rabanel J.M., Aoun V., Elkin I., Mokhtar M., Hildgen P. Drug-loaded nanocarriers: passive targeting and crossing of biological barriers. Curr Med Chem 2012, 19:3070-3102.
103. Rao D.D., Vorhies J.S., Senzer N., Nemunaitis J. siRNA vs. shRNA: similarities and differences. Adv Drug Deliv Rev 2009, 61:746-759.
104. Saha S., Adhikary A., Bhattacharyya P., Das T., Sa G. Death by design: where curcumin sensitizes drug-resistant tumors. Anticancer Res 2012, 32:2567-2584.
105. Sarisozen C., Vural I., Levchenko T., Hincal A.A., Torchilin V.P. Long-circulating PEG-PE micelles co-loaded with paclitaxel and elacridar (GG918) overcome multidrug resistance. Drug Deliv 2012, 19:363-370.
106. Sawicka M., Kalinowska M., Skierski J., Lewandowski W. A review of selected anti-tumor therapeutic agents and reasons for multidrug resistance occurrence. J Pharm Pharmacol 2010, 56:1067-1081.
107. Scheffer G.L., Wijngaard P.L., Flens M.J., Izquierdo M.A., Slovak M.L., Pinedo H.M., et al. The drug resistance-related protein LRP is the human major vault protein. Nat Med 1995, 1:578-582.
108. Schinkel A.H., Jonker J.W. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. Adv Drug Deliv Rev 2012, 64:138-153.
109. Shabbits J.A., Rajesh K., Mayer L.D. Molecular and pharmacological strategies to overcome multidrug resistance. Expert Rev Anticancer 2001, 1:585-594.
110. Shaffer B.C., Gillet J.P., Patel C., Baer M.R., Bates S.E., Gottesman M.M. Drug resistance: still a daunting challenge to the successful treatment of AML. Drug Resist Updat 2012, 15:62-69.
111. Sharma R.A., Gescher A.J., Steward W.P. Curcumin: the story so far. Eur J Cancer 2005, 41:1955-1968.
112. Sladek N.E. Aldehyde dehydrogenase-mediated cellular relative insensitivity to the oxazaphosphorines. Curr Pharm Des 1999, 5:607-625.
113. Song X.R., Cai Z., Zheng Y., He G., Cui F.Y., Gong D.Q., et al. Reversion of multidrug resistance by co-encapsulation of vincristine and verapamil in PLGA nanoparticles. Eur J Pharm Sci 2009, 37:300-305.
114. Stein W.D. Kinetics of the multidrug transporter (P-Glycoprotein) and its reversal. Physiol Rev 1997, 77:545-590.
115. Su W.P., Cheng F.Y., Shieh D.B., Yeh C.S., Su W.C. PLGA nanoparticles codeliver paclitaxel and Stat3 siRNA to overcome cellular resistance in lung cancer cells. Int J Nanomedicine 2012, 7:4269-4283.
116. Sun J., He Z.G., Cheng G., Wang S.J., Hao X.H., Zou M.J. Multidrug resistance P-glycoprotein: crucial significance in drug disposition and interaction. Med Sci Monit 2004, 10:RA5-RA14.
117. Susa M., Iyer A.K., Ryu K., Choy E., Hornicek F.J., Mankin H., et al. Inhibition of ABCB1 (MDR1) expression by an siRNA nanoparticulate delivery system to overcome drug resistance in osteosarcoma. PLoS One 2010, 5:e10764.
118. Szakács G., Paterson J.K., Ludwig J.A., Catherine B.G., Gottesman M.M. Targeting multidrug resistance in cancer. Nat Rev Drug Discov 2006, 5:219-234.
119. Talalay P. Chemoprotection against cancer by induction of phase 2 enzymes. Biofactors 2000, 12:5-11.
120. Thomas H., Coley H.M. Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein. Cancer Control 2003, 10:159-165.
121. Tiyaboonchai W., Tungpradit W., Plianbangchang P. Formulation and characterization of curcuminoids loaded solid lipid nanoparticles. Int J Pharm 2007, 337:299-306.
122. Tomita M., Kawakami H., Uchihara J.N., Okudaira T., Masuda M., Takasu N., et al. Curcumin (diferuloylmethane) inhibits constitutive active NF-kappaB, leading to suppression of cell growth of human T-cell leukemia virus type I-infected T-cell lines and primary adult T-cell leukemia cells. Int J Cancer 2006, 118:765-772.
123. Torchilin V.P., Trubetskoy V.S. Which polymers can make nanoparticulate drug carriers long-circulating?. Adv Drug Deliv Rev 1995, 16:141-155.
124. Townsend D.M., Tew K.D. The role of glutathione-S-transferase in anti-cancer drug resistance. Oncogene 2003, 22:7369-7375.
125. Tredan O., Galmarini C.M., Patel K., Tannock I.F. Drug resistance and the solid tumor microenvironment. J Natl Cancer Inst 2007, 99:1441-1454.
126. Twentyman P.R., Bleehen N.M. Resistance modification by PSC-833, a novel non-immunosuppressive cyclosporine. Eur J Cancer 1991, 27:1639-1642.
127. Ullah M.F. Cancer multidrug resistance (MDR): a major impediment to effective chemotherapy. Asian Pac J Cancer Prev 2008, 9:1-6.
128. Vahdat L.T., Pruitt B., Fabian C.J., Rivera R.R., Smith D.A., Tan-Chiu E., et al. Phase II study of eribulin mesylate, a halichondrin b analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 2009, 27:2954-2961.
129. Varkouhi A.K., Scholte M., Storm G., Haisma H.J. Endosomal escape pathways for delivery of biological. J Control Release 2011, 151:220-228.
130. Waehler R., Russell S.J., Curiel D.T. Engineering targeted viral vectors for gene therapy. Nat Rev Genet 2007, 8:573-587.
131. Wahl H., Tan L., Griffith K., Choi M., Liu J.R. Curcumin enhances Apo2L/TRAIL-induced apoptosis in chemoresistant ovarian cancer cells. Gynecol Oncol 2007, 105:104-112.
132. Wang Z., Zhang Y., Banerjee S., Li Y., Sarkar F.H. Notch-1 down-regulation by curcumin is associated with the inhibition of cell growth and the induction of apoptosis in pancreatic cancer cells. Cancer 2006, 106:2503-2513.
133. Wang X., Yang L., Chen Z.G., Shin D.M. Application of nanotechnology in cancer therapy and imaging. CA Cancer J Clin 2008, 58:97-110.
134. Wang Y., Suh Y.A., Fuller M.Y., Jackson J.G., Xiong S., Terzian T., et al. Restoring expression of wild-type p53 suppresses tumor growth but does not cause tumor regression in mice with a p53 missense mutation. J Clin Invest 2011, 121:893-904.
135. Wang T., Upponi J.R., Torchilin V.P. Design of multifunctional non-viral gene vectors to overcome physiological barriers: dilemmas and strategies. Int J Pharm 2012, 427:3-20.
136. Withoff S., De Jong S., De Vries E.G., Mulder N.H. Human DNA topoisomerase II: biochemistry and role in chemotherapy resistance. Anticancer Res 1996, 16:1867-1880.
137. Wong H.L., Bendayan R., Rauth A.M., Wu X.Y. Simultaneous delivery of doxorubicin and GG918 (Elacridar) by new polymer-lipid hybrid nanoparticles (PLN) for enhanced treatment of multidrug-resistant breast cancer. J Control Release 2006, 116:275-284.
138. L and IAP, the release of cytochrome C and inhibition of Akt. Carcinogenesis 2003, 24:1199-1208.
139. Wu H., Hait W.N., Yang J.M. Small Interfering RNA-induced suppression of MDR1 (P-Glycoprotein) restores sensitivity to multidrug-resistant cancer cells. Cancer Res 2003, 63:1515-1519.
140. Wu C.P., Ohnuma S., Ambudkar S.V. Discovering natural product modulators to overcome multidrug resistance in cancer chemotherapy. Curr Pharm Biotechnol 2011, 12:609-620.
141. Xiao Y., Hao H., Javadi A., Englec J., Xu W., Yang Y., et al. Multifunctional unimolecular micelles for cancer-targeted drug delivery and positron emission tomography imaging. Biomaterials 2012, 33:3071-3082.
142. Xiong X.B., Uludag H., Lavasanifar A. Novel biodegradable amphiphilic poly(ethylene oxide)-block-polyesters with grafted polyamines as supramolecular nanocarrier for efficient siRNA delivery. Biomaterials 2009, 30:242-253.
143. Yague E., Higgins C.F., Raguz S. Complete reversal of multidrug resistance by stable expression of small interfering RNAs targeting MDR1. Gene Ther 2004, 11:1170-1174.
144. Yague E., Arance A., Kubitza L., O'Hare M., Jat P., Ogilvie C.M., et al. Ability to acquire drug resistance arises early during the tumorigenesis process. Cancer Res 2007, 67:1130-1137.
145. Yan Y.D., Kim D.H., Sung J.H., Yong C.S., Choi H.G. Enhanced oral bioavailability of docetaxel in rats by four consecutive days of pre-treatment with curcumin. Int J Pharm 2010, 399:116-120.
146. Yang X., Hong H., Grailer J.J., Rowland I.J., Javadi A., Hurley S.A., et al. cRGD-functionalized, DOX-conjugated, and 64Cu-labeled superparamagnetic iron oxide nanoparticles for targeted anticancer drug delivery and PET/MR imaging. Biomaterials 2011, 32:4151-4160.
147. Ye M.X., Zhao Y.L., Li Y., Miao Q., Li Z.K., Ren X.L., et al. Curcumin reverses cis-platin resistance and promotes human lung adenocarcinoma A549/DDP cell apoptosis through HIF-1α and caspase-3 mechanisms. Phytomedicine 2012, 19:779-789.
148. Yin Q., Shen J., Chen L., Zhang Z., Gu W., Li Y. Overcoming multidrug resistance by co-delivery of Mdr-1 and survivin-targeting RNA with reduction-responsible cationic poly(β-amino esters). Biomaterials 2012, 33:6495-6506.
149. Youle R.J., Strasser A. The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol 2008, 9:47-59.
150. Yuen A.R., Sikic B.I. Multidrug resistance in lymphomas. J Clin Oncol 1994, 12:2453-2459.
151. Zaki N.M., Tirelli N. Gateways for the intracellular access of nanocarriers: a review of receptor-mediated endocytosis mechanisms and of strategies in receptor targeting. Expert Opin Drug Deliv 2010, 7:895-913.
152. Zhou G., Kuo M.T. NF-κ β-mediated induction of mdr1b expression by insulin in rat hepatoma cells. J Biol Chem 1997, 272:15174-15183.
153. Zhou H., Xia X.G., Xu Z. An RNA polymerase II construct synthesizes short-hairpin RNA with a quantitative indicator and mediates highly efficient RNAi. Nucleic Acids Res 2005, 33:e62.